AU720567B2 - Clostridium difficile toxins as mucosal adjuvants - Google Patents

Clostridium difficile toxins as mucosal adjuvants Download PDF

Info

Publication number
AU720567B2
AU720567B2 AU64047/96A AU6404796A AU720567B2 AU 720567 B2 AU720567 B2 AU 720567B2 AU 64047/96 A AU64047/96 A AU 64047/96A AU 6404796 A AU6404796 A AU 6404796A AU 720567 B2 AU720567 B2 AU 720567B2
Authority
AU
Australia
Prior art keywords
toxin
composition
urease
adjuvant
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU64047/96A
Other languages
English (en)
Other versions
AU6404796A (en
Inventor
Wende Lei
David M. Lyerly
Thomas P. Monath
James S. Moncrief
William D. Thomas Jr.
Francisco Javier Torres-Lopez
Zhenxi Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Vaccines US Inc
Original Assignee
OraVax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27053134&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU720567(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/543,708 external-priority patent/US5919463A/en
Application filed by OraVax Inc filed Critical OraVax Inc
Publication of AU6404796A publication Critical patent/AU6404796A/en
Application granted granted Critical
Publication of AU720567B2 publication Critical patent/AU720567B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU64047/96A 1995-07-07 1996-07-01 Clostridium difficile toxins as mucosal adjuvants Ceased AU720567B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US49938495A 1995-07-07 1995-07-07
US08/499384 1995-07-07
US08/543708 1995-10-16
US08/543,708 US5919463A (en) 1995-07-07 1995-10-16 Clostridium difficle toxins as mucosal adjuvants
PCT/US1996/011142 WO1997002836A1 (en) 1995-07-07 1996-07-01 Clostridium difficile toxins as mucosal adjuvants

Publications (2)

Publication Number Publication Date
AU6404796A AU6404796A (en) 1997-02-10
AU720567B2 true AU720567B2 (en) 2000-06-08

Family

ID=27053134

Family Applications (1)

Application Number Title Priority Date Filing Date
AU64047/96A Ceased AU720567B2 (en) 1995-07-07 1996-07-01 Clostridium difficile toxins as mucosal adjuvants

Country Status (9)

Country Link
EP (1) EP0837692B1 (enExample)
JP (1) JPH11509200A (enExample)
CN (1) CN1195297A (enExample)
AT (1) ATE195878T1 (enExample)
AU (1) AU720567B2 (enExample)
CA (1) CA2226339A1 (enExample)
DE (1) DE69610106D1 (enExample)
NZ (1) NZ312502A (enExample)
WO (1) WO1997002836A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9626864D0 (en) * 1996-12-24 1997-02-12 Smithkline Beecham Biolog Vaccine
AU746859B2 (en) * 1997-06-20 2002-05-02 Imperial College Of Science, Technology And Medicine Immonogenic fragments of toxin a of clostridium difficile
EP1568378B1 (en) * 1997-10-20 2016-03-16 Sanofi Pasteur Biologics, LLC Immunization against Clostridium difficile disease
EP2305303A3 (en) * 1997-10-20 2013-11-13 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
WO1999049890A1 (en) * 1998-03-31 1999-10-07 Daewoong Pharmaceutical Co., Ltd. A preventive and therapeutic vaccine for helicobacter pylori-associated diseases
WO2000061761A2 (en) * 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
US6733760B1 (en) 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
EP1169456B1 (en) * 1999-04-09 2012-07-11 Intercell USA, Inc. Recombinant production of Clostridium difficile Toxin A or Toxin B
WO2011126811A2 (en) 2010-03-30 2011-10-13 Pfenex Inc. High level expression of recombinant toxin proteins
KR101907434B1 (ko) 2010-09-03 2018-10-12 발네바 오스트리아 게엠베하 C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
US9290565B2 (en) * 2011-05-27 2016-03-22 Glaxosmithkline Biologicals, S.A. Immunogenic composition
AU2012349753A1 (en) 2011-12-08 2014-06-19 Novartis Ag Clostridium difficile toxin-based vaccine
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4944942A (en) * 1987-08-27 1990-07-31 Mobay Corporation Intranasal vaccination of horses with inactivated microorganisms or antigenic material
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
US5601823A (en) * 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
AU4773293A (en) * 1992-07-16 1994-02-14 Oxford University Multiple particulate antigen delivery system
GB9305919D0 (en) * 1993-03-22 1993-05-12 Health Lab Service Board Botulinum toxin polypeptides and their use as vaccines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HOLMGREN. J ET AL. AM. J. TROP. MED. HYG. 1994 VOL. 50 NO.5 SUPPL, PP 42-54 *

Also Published As

Publication number Publication date
AU6404796A (en) 1997-02-10
JPH11509200A (ja) 1999-08-17
ATE195878T1 (de) 2000-09-15
CN1195297A (zh) 1998-10-07
CA2226339A1 (en) 1997-01-30
NZ312502A (en) 1999-03-29
EP0837692B1 (en) 2000-08-30
EP0837692A4 (enExample) 1998-04-29
WO1997002836A1 (en) 1997-01-30
EP0837692A1 (en) 1998-04-29
DE69610106D1 (de) 2000-10-05

Similar Documents

Publication Publication Date Title
US5919463A (en) Clostridium difficle toxins as mucosal adjuvants
EP0837692B1 (en) Clostridium difficile toxins and toxoids as mucosal adjuvants
AU2005287502B2 (en) Immunogenic composition for use in vaccination against staphylococcei
HU222985B1 (hu) Nem-toxikus orális adjuvánsként használható mutáns enterotoxin
US20040087522A1 (en) Genetic vaccines for the production of chicken egg-yolk antibodies against enterotoxigenic escherichia coli and other pathogens
Ricci et al. Immunogenicity of the B monomer of Escherichia coli heat-labile toxin expressed on the surface of Streptococcus gordonii
AU4973200A (en) Recombinant toxin A/toxin B vaccine against Clostridium difficile
AU722653B2 (en) Intranasal vaccination against gastrointestinal disease
US6576244B1 (en) LT and CT in parenteral immunization methods against helicobacter infection
AU746859B2 (en) Immonogenic fragments of toxin a of clostridium difficile
US20030129198A1 (en) Methods to produce high levels of C. difficile toxins
US9119803B2 (en) Carious tooth vaccine and preparation method
US6036953A (en) Heterologous antigens in live cell V. cholerae strains
WO1998023763A9 (en) Heterologous antigens in live cell v. cholerae strains
Lee et al. The Progress
KR100207289B1 (ko) 헬리코박터 파이로리 유래의 항원단백질을 함유하는 리포좀
Lee et al. Towards vaccination: what progress?
Underdown Prospects for vaccination against H. pylori infection
CA2371022A1 (en) Genetically engineered oral commensal organisms as vaccines
Huang Protective immunity against Streptococcus mutans infection: Studies on nirB promoter controlled expression of cloned S. mutans adhesin in an attenuated Salmonella strain and its immunoenhancing role on host immunity
MXPA01003571A (en) Protective recombinant haemophilus influenzae

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired